Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine
therapy is the fundamental treatment against this entity, by directly or indirectly modifying …

Several endocrine therapies are currently available for the treatment of estrogen receptor
(ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine …

Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy.
However, substantial evidence indicates a continued role for ER signaling in tumor …

Selective estrogen receptor downregulators (SERDs) are a novel class of compounds
capable of reducing the ERα protein level and blocking ER activity. Therefore, SERDs are …

Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast
cancer (BC). Indeed, targeting the estrogen receptor (ER) signaling at different levels is a …

Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Introduction The selective estrogen receptor degrader (SERD) and full receptor antagonist
provides an important therapeutic option for hormone receptor (HR)-positive breast cancer …

Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER
positive breast cancers. Selective modulation of ER has been a therapeutic target for this …

Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER+)
breast cancer. ER can be activated in a ligand-dependent and independent manner …

Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …